Preventive and Personalized Medicine (2021-2023)

Asfendiyarov Kazakh National Medical University1 site in 1 country500 target enrollmentOctober 23, 2021

ConditionsHeart Attack

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Heart Attack
Sponsor: Asfendiyarov Kazakh National Medical University
Enrollment: 500
Locations: 1
Primary Endpoint: number of SNPs associated with Heart Attack
Status: Completed
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This is a GWAS study that aims to identify possible candidate genes associate to heart attack by exploring single nucleotide polymorphism (SNP) in a group of heart attack, in the Kazakh population. The investigators hypothesize that the careful phenotyping of the subject sand matching with increase the power to find SNP significantly associate with heart attack

Detailed Description

A genome-wide association study (GWAS) is an approach used in genetics research to associate specific genetic variations with particular diseases. The method involves scanning the genomes from many different people and looking for genetic markers that can be used to predict the presence of a disease. Once such genetic markers are identified, they can be used to understand how genes contribute to the disease and develop better prevention and treatment strategies.

Registry

clinicaltrials.gov

Start Date

October 23, 2021

End Date

January 20, 2023

Last Updated

3 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Asfendiyarov Kazakh National Medical University

Responsible Party

Principal Investigator

Ildar Fakhradiyev

Head of the Laboratory of Experimental Medicine

Asfendiyarov Kazakh National Medical University

Eligibility Criteria

Inclusion Criteria

•Persons of Kazakh nationality
•Age up to 59 years inclusive at the time of primary myocardial infarction
•Myocardial infarction was established in accordance with the EOC criteria: An increase and / or decrease in the level of cardiac troponin must be combined with at least one of the following: • Symptoms of myocardial ischemia • Newly occurring ischemic changes on the ECG • The appearance of a pathological Q wave • Identification according to imaging data methods of new areas of non-viable myocardium, or new areas of local contractility disorders of presumably ischemic etiology • Detection of a thrombus in the coronary arteries according to coronary angiography
•Presence of coronary angiography
•Persons able and willing to provide written informed consent;